ANRO
ANROHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, ANRO (ANRO) is listed under Biotechnology. At a $1.07B market cap, ANRO ranks as a small-cap company within healthcare. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD).
Market Cap
$1.07B
Beta
1.07
P/E (TTM)
—
P/E (Fwd)
-8.02
EPS (TTM)
$-2.45
EPS (Fwd)
$-3.43
ROE
-38.9%
ROA
-21.7%
Cash
$263.8M
Total Debt
$23.2M
Free CF
-$40.4M
52W Change
890.6%
Annual Financials
Cash vs Debt
ANRO holds $263.8M in cash against $23.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$40.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -38.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, ANRO has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ANRO's trajectory.